Core Viewpoint - The stock of Sihuan Pharmaceutical (02096) has seen an increase of over 4%, currently trading at 13.42 HKD with a transaction volume of 89.99 million HKD, following the announcement of a significant milestone in its clinical trial for the innovative anti-tumor drug SIM0505 [1] Group 1: Company Developments - Sihuan Pharmaceutical's subsidiary, Sihuan Zaiming, has completed the first dosing of the SIM0505 drug in a Phase I clinical trial for advanced solid tumor patients in the U.S. [1] - The trial aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SIM0505 [1] - SIM0505 is a novel ADC targeting CDH6, demonstrating higher affinity for tumor antigens compared to similar candidates [1] Group 2: Drug Characteristics - The drug utilizes Sihuan Zaiming's proprietary TOPO inhibitor as an effective payload, which not only exhibits strong anti-tumor activity but also has a high systemic clearance rate, thereby expanding the therapeutic window [1] - The Phase I dose-escalation study initiated in China has been expanded to include U.S. patients, with the mid-dose group now enrolling participants [1] - NextCure, Inc. has obtained exclusive global rights for SIM0505 outside of Greater China [1]
港股异动 | 先声药业(02096)涨超4% 先声再明新型ADC候选药物SIM0505完成Ⅰ期临床美国首例患者入组